



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRCC (m): 293T Lysate: sc-122749

## BACKGROUND

PRCC (papillary renal cell carcinoma) is a disorder which is marked by multiple tumors of varying size present in both kidneys of affected family members. The specific chromosomal translocation t(X;1)(p11.2;q21.2) observed in human PRCC results in the fusion of a PRCC gene at 1q21.2 to the TFE3 gene at Xp11.2. The translocation is predicted to result in the fusion of the amino-terminal region of the PRCC protein, which includes a proline-rich domain, to the entire TFE3 protein. PRCC is ubiquitously expressed in normal adult and fetal tissues and encodes a putative protein of 491 amino acids with a relatively high content of prolines. PRCC co-localizes within the nucleus with Sm pre-mRNA splicing factors and associates with a variety of pre-mRNA splicing factors. PRCC, usually a low-grade neoplasm, may be associated with cystic degeneration, hemorrhage and presence of abundant hemosiderin-laden macrophages (HLM).

## REFERENCES

1. Sidhar, S.K., Clark, J., Gill, S., Hamoudi, R., Crew, A.J., Gwilliam, R., Ross, M., Linehan, W.M., Birdsall, S., Shipley, J. and Cooper, C.S. 1996. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. *Hum. Mol. Genet.* 5: 1333-1338.
2. Weterman, M.A., Wilbrink, M. and Geurts van Kessel, A. 1996. Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. *Proc. Natl. Acad. Sci. USA* 93: 15294-15298.
3. Skalsky, Y.M., Ajuh, P.M., Parker, C., Lamond, A.I., Goodwin, G. and Cooper, C.S. 2001. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors. *Oncogene* 20: 178-187.
4. Wang, S., Filipowicz, E.A. and Schnadig, V.J. 2001. Abundant intracytoplasmic hemosiderin in both histiocytes and neoplastic cells: A diagnostic pitfall in fine-needle aspiration of cystic papillary renal-cell carcinoma. *Diagn. Cytopathol.* 24: 82-85.
5. LocusLink Report (LocusID: 179755). <http://www.ncbi.nlm.nih.gov/LocusLink/>

## CHROMOSOMAL LOCATION

Genetic locus: Prc (mouse) mapping to 3 F1.

## PRODUCT

PRCC (m): 293T Lysate represents a lysate of mouse PRCC transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

## STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.

## APPLICATIONS

PRCC (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive PRCC antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.